<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294619</url>
  </required_header>
  <id_info>
    <org_study_id>BPLG-005</org_study_id>
    <nct_id>NCT00294619</nct_id>
  </id_info>
  <brief_title>Treatment of Adults With Growth Hormone Deficiency</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioPartners GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety profile of a new weekly&#xD;
      administered growth hormone preparation compared with placebo in adults with growth hormone&#xD;
      deficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Fat Mass at the end of 26-week treatment from baseline</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the following parameters at the end of 26-week treatment from baseline; other body composition parameters, QoL Score, Serum IGF-I, IGFBP-3 levels &amp; SDS, Lipid profile, waist-to-hip ratio</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Pituitary Disorders</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>LB03002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>growth hormone</intervention_name>
    <description>subcutaneous injection, once-weekly</description>
    <arm_group_label>LB03002</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of at least 23 years and not more than 70 years of age&#xD;
&#xD;
          -  GHD of either adult onset(AO)or Childhood onset(CO), either idiopathic or secondary to&#xD;
             pituitary disease&#xD;
&#xD;
          -  Confirmed diagnosis of GHD defined&#xD;
&#xD;
          -  IGF-1 SDS â‰¤ -1 at screening&#xD;
&#xD;
          -  No exposure to rhGH within the last 6 months&#xD;
&#xD;
          -  Patients with adequate adrenal function, which is confirmed by ACTH stimulation test&#xD;
             at screening; or Patients with known secondary hypoadrenalism on adequate&#xD;
             glucocorticoid replacement therapy&#xD;
&#xD;
          -  If applicable, hormone replacement therapies for any other hormone deficiencies,&#xD;
             adequate and stable for at least 3 months before study entry&#xD;
&#xD;
          -  Women of child-bearing potential to be using a reliable method of contraception at the&#xD;
             screening and be willing to use it throughout the study&#xD;
&#xD;
          -  A negative serum pregnancy test is required at screening for females of child-bearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malignancy other than cranial tumor or leukemia causing GHD or fully&#xD;
             treated basal cell carcinoma&#xD;
&#xD;
          -  Evidence of active malignancy&#xD;
&#xD;
          -  Evidence of growth of pituitary adenoma or other intracranial tumor within the last 12&#xD;
             months, or patients without MRI or CT data to confirm the tumor stability within the&#xD;
             last 12 months&#xD;
&#xD;
          -  Significant hepatic dysfunction&#xD;
&#xD;
          -  Chronic renal impairment&#xD;
&#xD;
          -  Clinically significant pulmonary, cardiac, hepatic, renal, or neuromuscular disease&#xD;
&#xD;
          -  Prader-Willi syndrome&#xD;
&#xD;
          -  Acute severe illness in the last 6 months&#xD;
&#xD;
          -  Benign intracranial hypertension&#xD;
&#xD;
          -  Active Cushing's syndrome within the last 12 months&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Patients with overt diabetes mellitus or evidence of persistent impaired glucose&#xD;
             tolerance&#xD;
&#xD;
          -  Severe psychiatric disease or patients who cannot understand the objective and methods&#xD;
             of the study or patients with current alcohol abuse&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known hypersensitivity to any ingredient of the study drug&#xD;
&#xD;
          -  Inability to undergo scanning by dual-energy X ray absorptiometry (DXA) due to a body&#xD;
             weight more than 130 kg or in situ internal or external devices known to interfere&#xD;
             with DXA scanning&#xD;
&#xD;
          -  Weight reducing drugs or appetite suppressants&#xD;
&#xD;
          -  Anabolic steroids other than gonadal steroid replacement therapy within 2 months&#xD;
             before study entry&#xD;
&#xD;
          -  Methylphenidate within 2 months before study entry&#xD;
&#xD;
          -  Systemic corticosteroids other than in replacement doses within the 3 months before&#xD;
             study entry.&#xD;
&#xD;
          -  History of non-compliance with medications, un-cooperativeness or drug abuse&#xD;
&#xD;
          -  Patients participating in another study parallel to, or within 6 months prior to study&#xD;
             entry, or previous participation in this study&#xD;
&#xD;
          -  Patients who are not able to comply with the study protocol for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HJ Ji, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>LG Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth hormone deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

